Skip to content
Study details
Enrolling now

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Southwest Autism Research & Resource Center
NCT IDNCT04060030ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

80

Study length

about 5.7 years

Ages

2.5–5

Locations

2 sites in AZ, NY

About this study

Researchers are testing whether leucovorin calcium, a medication, helps improve social communication and reduce symptoms in young children with autism spectrum disorder (ASD) who have language delays. The trial will last about 26 weeks and involve approximately 80 children aged 2.5 to 5 years old.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Levoleucovorin Calcium
PhasePhase 2
DrugLevoleucovorin Calcium
Routeinjection
Primary goalEvaluate the change in social communication symptoms

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

Antidotes, Deterrents, and Toxicologic Agents

Drug routes

injection (Injection)

Endpoints

Primary: Evaluate the change in social communication symptoms

Secondary: Evaluate adverse effect symptoms in young children with ASD, Evaluate change in specific autism symptom severity, Evaluate the change in effects of autism symptoms on family members, Evaluate the change in stereotypical autism symptoms, Evaluate the overall change in core ASD symptoms of social communication, Evaluate the overall change in core ASD symptoms of social communication using a blind observer, Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD

Body systems

Psychiatry / Mental Health